ADSL and infectious disease: The substitution of leucine with 6-aminohexanoic acid in AMPs represents a promising strategy for addressing resistant bacteria by reducing toxicity and maintaining antibacterial efficacy, offering potential solutions to combat infectious diseases in the future.